But new data from CheckMate-142 announced at the European Society for Medical Oncology (ESMO) conference showed the combination worked in patients who have received no prior treatment for MSI-high ...

And, the answer is, in these two cases, yes." The annual ESMO conference — like its sister meeting, the American Society of Medical Oncology, usually held in May and/or June — is a yearly who ...

November 6, 2024Personalis, Inc. misses on earnings expectations. Reported EPS is $-0.64 EPS, expectations were $-0.33. Operator: Good afternoon, everyone, and welcome to Personalis Third Quarter 2024 ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

For BNT113, our mRNA vaccine candidate against HPV16 positive cancer, we presented data from two trials at the ESMO conference. One data set was from the safety run-in cohort of our potentially ...

at the European Society for Medical Oncology (ESMO) conference in September 2024. The ESMO presentation further revealed statistically significant improvement in survival for this triple ...

Greetings, and welcome to the Incyte third-quarter financial results conference call and webcast. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to turn ...

Issuer: CureVac / Key word (s): Conference CureVac to Present at the 12th International mRNA Health Conference 04.11.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this ...

esmo group has launched its latest product—the Apollo Quad Handler. Designed to bridge the gap between the engineering and ...

Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine ...

Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz Director, Investor Relations. Please go ahead.